Figure 5

Effects of TGF-β1 on tumor cell survival. (A) BxPC3 cells were pre-incubated with 5 and 10 ng/ml of TGF-β1 or 1% FBS as a control for 24 h and then treated with various concentrations of cisplatin for additional 48 h. Cell viability was determined by the MTT assay. (B) IC₅₀ values (μg/ml) of cisplatin were calculated based on the above treatment in the tumor cells. *represents significant difference of IC₅₀ value between group '1%FBS + 5 ng/ml TGF-β1' and group '1%FBS' (P = 0.03); **represents significant difference between group '1%FBS + 10 ng/ml TGF-β1' and group '1%FBS' (P = 0.044).